Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Lili Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-4119-5270; OpenAlex author ID A5101838435. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 7

  1. Corrigendum to "Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC." [Biochem. Biophys. Res. Commun. 499 (3… Co-author DOI 10.1016/j.bbrc.2023.149426↗
  2. METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity. Co-author DOI 10.1007/s13402-023-00829-2↗
  3. Reciprocal regulation of LOXL2 and HIF1α drives the Warburg effect to support pancreatic cancer aggressiveness. Co-author DOI 10.1038/s41419-021-04391-3↗
  4. TRIM50 Suppresses Pancreatic Cancer Progression and Reverses the Epithelial-Mesenchymal Transition via Facilitating the Ubiquitous Degradation of Snail1. First author DOI 10.3389/fonc.2021.695740↗
  5. Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer. Co-author DOI 10.7150/ijbs.49243↗
  6. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis. Co-author DOI 10.1002/jcb.29433↗
  7. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC. Co-author DOI 10.1016/j.bbrc.2018.03.194↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li-Peng Hu · 6 shared papers, 2018–2024 · strength 0.82
  2. Shu‐Heng Jiang · 6 shared papers, 2018–2024 · strength 0.82
  3. Zhigang Zhang · 5 shared papers, 2018–2024 · strength 0.71
  4. Rongkun Li · 5 shared papers, 2020–2023 · strength 0.69
  5. Qing Li · 4 shared papers, 2018–2024 · strength 0.52
  6. Yongwei Sun · 3 shared papers, 2018–2024 · strength 0.40
  7. Minwei Yang · 2 shared papers, 2018–2024 · strength 0.29
  8. Xiaoyan Cao · 2 shared papers, 2018–2024 · strength 0.29
  9. Xu Wang · 2 shared papers, 2021 · strength 0.23
  10. Xueli Zhang · 1 shared paper, 2023 · strength 0.19
  11. Botai Li · 1 shared paper, 2023 · strength 0.19
  12. Dejun Liu · 1 shared paper, 2021 · strength 0.16
  13. Hengchao Li · 1 shared paper, 2021 · strength 0.12
  14. Yongsheng Jiang · 1 shared paper, 2021 · strength 0.11
  15. Xin Xing · 1 shared paper, 2021 · strength 0.11
  16. Qin Yang · 1 shared paper, 2021 · strength 0.11
  17. Bingyan Liu · 1 shared paper, 2020 · strength 0.11
  18. Mingyi Shang · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.